FDA Grants Breakthrough Therapy Designation to Multiple Myeloma Drug Elotuzumab

By Rhonda Reinhart

Adam Voorhes

For patients with multiple myeloma, a progressive blood cancer that originates in the bone marrow, clinical trials of the experimental drug elotuzumab have shown promise in treating the disease. Now the U.S. Food and Drug Administration has taken notice.

Based on results from a Phase 2 trial last summer, which showed that patients treated with elozutumab in combination with two other therapies had a median progression-free survival rate of 33 months, the FDA has designated elotuzumab as a breakthrough therapy, meaning the agency will expedite the development and review of the drug.

Elotuzumab, which is now in Phase 3 trials, is being co-developed by Bristol-Myers Squibb and AbbVie.